Talks (130)
Air Time: 469:42:46
MMF withdrawal in SLE
Jan 31
mTOR inhibition in Sarcoid
Jan 31
Hidradenitis
Jan 31
Pyoderma pearl
Jan 31
Refractory Myositis Treatment
Jan 31
SSc Treatments
Jan 31
SSc Trials
Jan 31
Metabolic myopathy 2
Jan 31
Metabolic Myopathy 1
Jan 31
Polymyositis Mimics
Jan 31
Winter Rheumatology
Jan 31
AAV Maintenance Strategies
Jan 05
LoVAS 2 Year Data
Jan 05
Adiposity and TNFi Response
Jan 05
Biosimilar TCZ
Jan 05
Economic insecurity and lupus outcomes
Jan 05
Methotrexate holding in COVID-19 vaccine
Jan 05
Benralizumab in EGPA
Dec 01
CH in GCA
Dec 01
Pregnancy and Vasculitis
Dec 01
Long COVID and Fibro
Dec 01
Steroid PRO
Dec 01
Obinutuzumab in LN
Dec 01
AVB in Ro+ Disease
Dec 01
Cancer and autoantibodies in SSc
Dec 01
Abatacept in PMR
Dec 01
4th COVID Vaccine
Dec 01
Pregnancy outcomes in vasculitis
Nov 29
Split dose MTX
Nov 29
Optic nerve sheath thickness
Nov 29
TA US after treatment
Nov 29
Dupilumab for EGPA?
Nov 29
Avacopan in the real world part 2
Nov 29
Avacopan in the real world
Nov 29
Real world PEXIVAS
Nov 29
Telitacicept in RA
Nov 29
IgG4-RD Maintenance
Nov 29
PET imaging in GCA
Oct 31
Sarilumab in PMR
Oct 31
Response criteria in Ra
Oct 31
Biopsy to guide RA treatment
Oct 31
Vaccines with MTX
Oct 31
AAV across ages
Oct 31
HCQ Monitoring
Oct 31
Dobbs Decision in the US
Oct 31
Mineralization and pain in knee OA
Oct 31
PRESTO
Oct 31
MTX with TNFi survival
Oct 02
Withdrawing steroids in RA
Oct 02
Initiating RA treatment
Oct 02
The future burden of RA
Oct 02
When to taper meds in lupus
Oct 02
Gout management during COVID
Oct 02
Interferon and dermato
Oct 02
Sclerostin and CV Risk
Oct 02
Low dose prednisone and OP
Oct 02
Timing of joint surgery
Oct 02
Biosimilars
Aug 31
Alcohol and hip replacements
Aug 31
Risks and benefits of PJP ppx
Aug 31

RemoveCancel